ATryn®
(Antithrombin [Recombinant])

PrintIncrease text size
  • ATryn is a recombinant antithrombin produced by DNA technology.
  • ATryn is a sterile lyophilized powder suitable for intravenous administration after reconstitution.
  • Each single dose vial of ATryn contains approximately 1750 IU Antithrombin (Recombinant).

____________________________________________________________________________________

Indications and Usage:

ATryn [Antithrombin (Recombinant)] is indicated for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients.

It is not indicated for treatment of thromboembolic events in hereditary antithrombin deficient patients.

Important Safety Information:

ATryn is contraindicated in patients with known hypersensitivity to goat and goat milk proteins.

Allergic-type hypersensitivity reactions are possible. Patients must be closely monitored and carefully observed for any symptoms throughout the infusion period. Patients should be informed of the early signs of hypersensitivity reactions including hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis. If these symptoms occur during administration, treatment must be discontinued immediately. Adding ATryn to or withdrawing ATryn from anticoagulants that use antithrombin to exert their anticoagulative effects may alter this effect. To avoid excessive or insufficient anticoagulation, coagulation tests suitable for the anticoagulant used (e.g., aPTT and anti-Factor Xa activity) are to be performed regularly, at close intervals, and in particular in the first hours following the start or withdrawal of ATryn. In such situations, patients should be monitored for the occurrence of bleeding or thrombosis.

The serious adverse reaction that has been reported in clinical studies is hemorrhage (intra-abdominal, hemarthrosis, and post procedural). The most common adverse events reported in clinical trials at a frequency of >5% are hemorrhage and infusion site reaction.

For more information, please see Full Prescribing Information.

To order ATryn, click here.

® Trademark of Lundbeck Inc., Deerfield, IL 60015, U.S.A.

 

 

 

Important Contact Information

Please visit Customer Support for important contact information relating to our products including:

  • Medical information
  • Drug safety information
  • Product ordering information

* Dial 911 if you are experiencing a medical emergency *

 

 

 

ATryn® (Antithrombin [Recombinant])

Approved by the FDA in February 2009 for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients.  It is not indicated for treatment of thromboembolic events in hereditary antithrombin deficient patients.

This site contains medical information that is intended for residents of the United States only and is not meant to
substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns.
Use and access of this site is subject to the terms and conditions as set out in our Privacy Policy and Terms of Use.
© Copyright 2010 Lundbeck Inc. All rights reserved.
Phone: 866-337-6996
Fax: 847.282.1001
contact@lundbeck.com